Risk factors and survival outcome in cerebral metastatic breast cancer

Bachmann, C.; Schmidt, S.; Staebler, A.; Schittenhelm, J.; Wallwiener, D.; Grischke, E.
March 2014
Medical Oncology;Mar2014, Vol. 31 Issue 3, p1
Academic Journal
No abstract available.


Related Articles

  • Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Lobbezoo, D J A; van Kampen, R J W; Voogd, A C; Dercksen, M W; van den Berkmortel, F; Smilde, T J; van de Wouw, A J; Peters, F P J; van Riel, J M G H; Peters, N A J B; de Boer, M; Peer, P G M; Tjan-Heijnen, V C G // British Journal of Cancer;4/28/2015, Vol. 112 Issue 9, p1445 

    Background:We aimed to determine the prognostic impact of time between primary breast cancer and diagnosis of distant metastasis (metastatic-free interval, MFI) on the survival of metastatic breast cancer patients.Methods:Consecutive patients diagnosed with metastatic breast cancer in 2007-2009...

  • Medical treatment of early breast cancer. I: adjuvant treatment. Smith, Ian E.; Chua, Susan // BMJ: British Medical Journal (International Edition);1/7/2006, Vol. 332 Issue 7532, p34 

    The article discusses medical treatments in early breast cancer and the side effects of endocrine therapy and chemotherapy. The major risk factors for metastatic disease include the absence of estrogen and progestogen receptors. Statistics are given for breast cancer mortality after treatment...

  • Survival in breast cancer not affected by coping style.  // Nursing Standard;12/10/2008, Vol. 23 Issue 14, p15 

    The article reports on the findings of the research conducted by researchers from Spain and Australia. According to researchers, psychosocial factors are not key influences in breast cancer outcomes. In addition, researchers also found out that there is no relationship between psychosocial...

  • The effect of delays in treatment for breast cancer metastasis on survival. Jung, Su; Sereika, Susan; Linkov, Faina; Brufsky, Adam; Weissfeld, Joel; Rosenzweig, Margaret // Breast Cancer Research & Treatment;Dec2011, Vol. 130 Issue 3, p953 

    It is generally accepted that delay in receiving treatment for breast cancer results in adverse outcomes. The purpose of this study was to evaluate the impact of delay in treatment after the diagnosis of metastatic disease on survival measured from metastatic breast cancer diagnosis and from...

  • Risk of Developing Brain Metastases in Patients with Metastatic Breast Cancer. Ershler, William B. // Clinical Oncology Alert;Sep2011, Vol. 27 Issue 9, p70 

    The author discusses a study by F. Heitz and colleagues, which examined the risk of developing cerebral metastases in metastatic breast cancer patients. He states that although the study is retrospective, it used a substantial sample size, and opines that risk factors should be examined before...

  • Excellent response to letrozole in brain metastases from breast cancer. Goyal, S.; Puri, T.; Julka, P. K.; Rath, G. K. // Acta Neurochirurgica;Jun2008, Vol. 150 Issue 6, p613 

    Breast cancer with multiple parenchymal brain metastases carries an extremely poor outcome. Cranial radiotherapy improves survival by only a few months and the role of systemic therapy is marginal and largely unexplored. We report a patient with recurrent carcinoma of breast presenting with...

  • The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Mitri, Zahi; Constantine, Tina; O'Regan, Ruth // Chemotherapy Research & Practice;2012, p1 

    Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20-30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the...

  • risky business. Messina, Lauren // Vegetarian Times;Oct2000, Issue 278, Special Section p8 

    Discusses the risk factors for breast cancer.

  • Update on triple-negative breast cancer: prognosis and management strategies. Brouckaert, Olivier; Wildiers, Hans; Floris, Giuseppe; Neven, Patrick // International Journal of Women's Health;2012 Part 2, Vol. 4, p511 

    Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15%-20% of all breast cancers belong to this phenotype that has distinct risk factors, distinct molecular features, and a...

  • Targeting Therapies in the Management of Breast Carcinoma. Kaur, Paramjeet; Chauhan, Ashok K.; Singh, Gajender; Kataria, Sant Parkash // Internet Journal of Oncology;2009, Vol. 6 Issue 2, p23 

    One of the oldest molecular target approaches in breast cancer is the targeting of the estrogen receptor with tamoxifen which is responsible for improvement in outcome, reduced the risk of new primary breast cancer and improves survival. Targeted therapies are now a component of treatment for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics